Testing shorter treatment options for isoniazid-monoresistant tuberculosis.
A Phase 2C Randomized, Controlled, Open-Label Trial of Novel Shortened Regimens for the Treatment of Isoniazid-Monoresistant TB (IMR-TB)
This study is looking at new, shorter treatment options for people with isoniazid-monoresistant tuberculosis (IMR-TB) to see if a 4-month treatment works better and is easier to handle than the usual 6-month treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10764464 on NIH RePORTER |
What this research studies
This research investigates new, shorter treatment regimens for patients with isoniazid-monoresistant tuberculosis (IMR-TB), a condition affecting over a million people each year. The study will compare two novel 4-month treatment options against the current standard 6-month regimen to see which is more effective and has fewer side effects. Participants will be monitored for how quickly their sputum cultures clear and for any serious adverse events. The goal is to improve treatment outcomes and reduce the burden of IMR-TB.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals aged 21 and older who have been diagnosed with isoniazid-monoresistant tuberculosis.
Not a fit: Patients with drug-susceptible tuberculosis or those who do not have isoniazid-monoresistant tuberculosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and shorter treatment options for patients with IMR-TB.
How similar studies have performed: Previous research has shown success in shortening treatment durations for other forms of tuberculosis, suggesting potential for similar advancements in IMR-TB.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Velasquez, Gustavo Eduardo — University of California, San Francisco
- Study coordinator: Velasquez, Gustavo Eduardo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.